Skip to main content
Sunshine Lake Pharma Co., Ltd. logo

Sunshine Lake Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 6887 ISIN · CNE1000070M8 HKEX Manufacturing
Filings indexed 77 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country HK Hong Kong
Listing HKEX 6887

About Sunshine Lake Pharma Co., Ltd.

https://www.hecpharm.com

Sunshine Lake Pharma Co., Ltd. is a research-based, vertically integrated pharmaceutical company engaged in the R&D, production, and commercialization of innovative pharmaceutical products. Its core therapeutic focus areas include infectious diseases, chronic diseases, and oncology, with pipeline assets also targeting conditions such as psoriasis and rheumatoid arthritis. The company emphasizes the globalization and accelerated commercialization of its innovative drug portfolio. To enhance its R&D capabilities, Sunshine Lake Pharma utilizes advanced technology platforms, notably through strategic investments in joint ventures focused on AI and robotics for drug discovery. It also participates in the sourcing and supply of pharmaceutical and animal health ingredients.

Recent filings

Filing Released Lang Actions
INSIDE INFORMATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE IN RESPECT OF THE H SHARE FULL CIRCULATION
Regulatory Filings
2026-05-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings
2026-05-06 English
VOLUNTARY ANNOUNCEMENT IN RELATION TO THE MARKETING APPROVAL OF INSULIN GLARGINE INJECTION BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA)
Regulatory Filings
2026-05-04 English
2025 Environmental, Social and Governance Report
Regulatory Filings
2026-04-30 English
Annual Report 2025
Regulatory Filings
2026-04-30 English
INSIDE INFORMATION ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION BY THE COMPANY
Capital/Financing Update Classification · 82% confidence The document is an official announcement under the Hong Kong Listing Rules disclosing the CSRC’s filing notice for the conversion (“full circulation”) of Domestic Shares into H Shares, including detailed share conversion tables and post‐conversion share structure. This is not a financial report, vote declaration, or insider dealing notice but a capital structure change update. Therefore it is best classified as a Capital/Financing Update (CAP).
2026-04-29 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.